Security
Nuvation Bio Inc. · NUVB.WS
NUVB.WSNYSEWarrantHistorical · closed Feb 10, 2026CIK 1811063Updated Oct 6, 2026
Name history
Panacea Acquisition Corp · through Feb 11, 2021
Current security for this SEC filerNUVB · NYSE
NUVB.WS price & chart
Historical security
This listing closed Feb 10, 2026. Live provider charts are shown only for current listings.
Current security: NUVB
About the company
Nuvation Bio is a global oncology company focused on tackling some of the toughest challenges in cancer treatment with the goal of developing therapies that create a profound, positive impact on patients’ lives. Nuvation Bio’s diverse pipeline includes taletrectinib (IBTROZI®), a next-generation ROS1 inhibitor; safusidenib, a brain-penetrant IDH1 inhibitor; and an innovative drug-drug conjugate (DDC) program.
In the news
No coverage from other publishers is available.
Recent filings
4 filing
144 filing
Results of Operations and Financial Condition
Items 2.02, 9.01
10-Q filing
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · Other Events
Items 2.03, 8.01, 9.01
Show 5 more recent filings
Entry into a Material Definitive Agreement · Termination of a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · Other Events
Items 1.01, 1.02, 2.03, 8.01, 9.01
424B5 filing
305B2 filing
FWP - filed by Nuvation Bio Inc. regarding Nuvation Bio Inc.
424B5 filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 601,561,000Source | 571,579,000Source | 744,503,000Source | 647,225,000Source | 594,796,000Source | 610,241,000Source | 492,489,000Source | 613,125,000Source | 594,822,000Source | 540,626,000Source | 621,484,000Source | 672,141,000Source |
| Property, Plant and Equipment, NetUSD | 560,000Source | 719,000Source | 715,000Source | 615,000Source | 751,000Source | 535,000Source | 562,000Source | 686,000Source | 564,000Source | 586,000Source | 717,000Source | 894,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 98,897,000Source | 30,036,000Source | 258,604,000Source | 247,970,000Source | 34,285,000Source | 125,391,000Source | 47,977,000Source | 34,510,000Source | 164,086,000Source | 35,723,000Source | 42,649,000Source | 101,099,000Source |
| Accounts Receivable | —Source | —Source | —Source | —Source | —Source | —Source | —Source | — | —Source | —Source | — | — |
| Inventory, NetUSD | 5,710,000Source | — | 19,901,000Source | 552,000Source | — | 15,844,000Source | 14,000Source | — | 11,411,000Source | — | — | — |
| Assets, CurrentUSD | 577,530,000Source | 564,985,000Source | 726,432,000Source | 623,208,000Source | 587,172,000Source | 591,529,000Source | 475,567,000Source | 608,055,000Source | 571,519,000Source | 526,255,000Source | 616,434,000Source | 667,318,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 8,925,000Source | 11,598,000Source | 13,861,000Source | 8,257,000Source | 5,991,000Source | 15,972,000Source | 8,415,000Source | 6,796,000Source | 11,536,000Source | 7,271,000Source | 1,519,000Source | 3,819,000Source |
| Operating Lease, Right-of-Use AssetUSD | 4,329,000Source | 2,472,000Source | 3,240,000Source | 4,641,000Source | 2,723,000Source | 3,598,000Source | 5,334,000Source | 3,168,000Source | 3,918,000Source | 2,402,000Source | 3,605,000Source | 3,791,000Source |
| Other Assets, NoncurrentUSD | 7,462,000Source | 480,000Source | 3,824,000Source | 6,616,000Source | 1,075,000Source | 3,824,000Source | 6,616,000Source | 1,075,000Source | 7,607,000Source | 6,616,000Source | 587,000Source | — |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 275,679,000Source | 68,865,000Source | 490,639,000Source | 274,318,000Source | 62,665,000Source | 290,677,000Source | 73,029,000Source | 19,083,000Source | 289,106,000Source | 76,838,000Source | 16,362,000Source | 17,065,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 1,404,799,000Source | 1,362,631,000Source | 1,429,288,000Source | 1,396,220,000Source | 1,078,547,000Source | 1,431,214,000Source | 1,382,894,000Source | 952,807,000Source | 1,421,273,000Source | 1,373,958,000Source | 947,745,000Source | 927,604,000Source |
| Retained Earnings (Accumulated Deficit)USD | -1,078,778,000Source | -861,298,000Source | -1,172,813,000Source | -1,022,986,000Source | -820,088,000Source | -1,109,973,000Source | -963,979,000Source | -357,596,000Source | -1,115,370,000Source | -910,743,000Source | -342,804,000Source | -267,002,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -139,000Source | 1,381,000Source | -2,611,000Source | -327,000Source | -1,266,000Source | -1,677,000Source | 545,000Source | -1,169,000Source | -187,000Source | 573,000Source | 181,000Source | -5,526,000Source |
| Stockholders' Equity Attributable to ParentUSD | 325,882,000Source | 502,714,000Source | 253,864,000Source | 372,907,000Source | 257,193,000Source | 319,564,000Source | 419,460,000Source | 594,042,000Source | 305,716,000Source | 463,788,000Source | 605,122,000Source | 655,076,000Source |
| Liabilities and EquityUSD | 601,561,000Source | 571,579,000Source | 744,503,000Source | 647,225,000Source | 594,796,000Source | 610,241,000Source | 492,489,000Source | 613,125,000Source | 594,822,000Source | 540,626,000Source | 621,484,000Source | 672,141,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 68,131,000Source | 59,035,000Source | 86,755,000Source | 66,356,000Source | 51,095,000Source | 79,522,000Source | 52,772,000Source | 15,762,000Source | 82,231,000Source | 58,244,000Source | 13,974,000Source | 13,161,000Source |
| Operating Lease, Liability, CurrentUSD | 1,871,000Source | 1,781,000Source | 1,715,000Source | 1,808,000Source | 2,076,000Source | 1,838,000Source | 1,889,000Source | 2,023,000Source | 1,880,000Source | 1,663,000Source | 1,972,000Source | 1,206,000Source |
| Accounts Payable, CurrentUSD | 15,360,000Source | 12,380,000Source | 12,089,000Source | 22,419,000Source | 5,211,000Source | 22,435,000Source | 10,537,000Source | 2,436,000Source | 9,479,000Source | 6,348,000Source | 2,209,000Source | 2,139,000Source |
| Operating Lease, Liability, NoncurrentUSD | 2,970,000Source | 985,000Source | 1,910,000Source | 3,399,000Source | 972,000Source | 2,199,000Source | 3,839,000Source | 1,509,000Source | 2,543,000Source | 969,000Source | 2,035,000Source | 3,054,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 32,579,000Source | 23,506,000Source | 45,204,000Source | 23,998,000Source | 19,974,000Source | 32,864,000Source | 23,892,000Source | 11,303,000Source | 45,183,000Source | 32,833,000Source | 9,793,000Source | 9,816,000Source |
| Deferred Revenue, NoncurrentUSD | 144,621,000Source | — | 151,122,000Source | 142,780,000Source | — | 151,886,000Source | — | — | 145,819,000Source | — | — | — |
| Long-term DebtUSD | 47,089,000Source | — | 242,624,000Source | 46,974,000Source | — | 47,327,000Source | — | — | 47,208,000Source | — | — | — |
| Preferred Stock, Value, Issued | — | — | — | — | —Source | — | — | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation and amortization | — | — | — | — | — | — | —Source | —Source | —Source | —Source | —Source | —Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 9,033,000Source | 7,854,000Source | 35,894,000Source | 32,275,000Source | 19,513,000Source | 16,292,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | 6,647,000Source | -12,313,000Source | 3,354,000Source | 12,722,000Source | — | — |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 12,956,000Source | 4,189,000Source | 3,131,000Source | -1,654,000Source | 70,000Source | -1,786,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | 5,069,000Source | -42,627,000Source | -173,427,000Source | -130,413,000Source | -67,999,000Source | -96,108,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -43,636,000Source | 54,182,000Source | 99,520,000Source | 122,703,000Source | 8,921,000Source | 63,457,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 44,000Source | 548,000Source | 202,535,000Source | 331,000Source | 628,000Source | 1,327,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -38,695,000Source | 12,254,000Source | 128,363,000Source | -6,926,000Source | -58,450,000Source | -31,324,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 98,897,000Source | 30,036,000Source | 258,604,000Source | 247,970,000Source | 125,391,000Source | 47,977,000Source | 164,086,000Source | 35,723,000Source | 42,649,000Source | 101,099,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | — | 2,882,000Source | 341,000Source | — | — |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | — | — | -172,000Source | 151,000Source | -265,000Source | 453,000Source | — | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 8,021,000Source | 7,476,000Source | 10,460,000Source | 12,031,000Source | 9,033,000Source | 7,854,000Source | 35,894,000Source | 32,275,000Source | 19,513,000Source | 16,292,000Source |
| Amortization of Debt Issuance CostsUSD | — | — | 213,000Source | — | — | 11,000Source | 321,000Source | 0Source | 662,000Source | — | — | — |
| Equity Securities, FV-NI, Gain (Loss)USD | — | — | — | — | — | — | — | — | — | — | 0Source | -172,000Source |
| Foreign Currency Transaction Gain (Loss), UnrealizedUSD | — | — | — | — | — | — | 21,000Source | -248,000Source | 1,085,000Source | — | — | — |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | 4,000Source | 0Source | 1,000Source | -34,000Source | — | — | -33,000Source | -229,000Source | -10,000Source | -50,000Source |
| General and Administrative ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 28,533,000Source | 31,919,000Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| InterestExpenseNonoperatingUSD | — | — | 6,534,000Source | 120,000Source | 6,759,000Source | 421,000Source | 6,708,000Source | 54,000Source | 13,682,000Source | 341,000Source | — | — |
| Market Risk Benefit, Change in Fair Value, Gain (Loss)USD | — | — | — | 500,000Source | — | — | — | -800,000Source | 800,000Source | 900,000Source | 500,000Source | 10,200,000Source |
| Marketable Securities, Gain (Loss), Excluding Other-than-temporary Impairment LossUSD | — | — | 0Source | -11,000Source | 9,000Source | -1,000Source | 8,000Source | 3,000Source | 5,000Source | -12,000Source | — | — |
| Marketable Securities, Unrealized Gain (Loss)USD | — | — | — | — | — | — | 1,214,000Source | 490,000Source | 746,000Source | -157,000Source | 5,568,000Source | -5,569,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -55,792,000Source | -41,210,000Source | -62,840,000Source | -59,007,000Source | 5,397,000Source | -53,236,000Source | -204,627,000Source | -567,939,000Source | -75,802,000Source | -104,199,000Source |
| Nonoperating Income (Expense)USD | — | — | 642,000Source | 6,891,000Source | -11,804,000Source | 4,582,000Source | 1,516,000Source | 5,768,000Source | 8,437,000Source | 24,688,000Source | 24,020,000Source | 15,535,000Source |
| Operating ExpensesUSD | — | — | 66,205,000Source | 47,313,000Source | 82,723,000Source | 68,422,000Source | 79,347,000Source | 62,088,000Source | 275,966,000Source | 593,422,000Source | 99,822,000Source | 119,734,000Source |
| Operating Lease, ExpenseUSD | — | — | 500,000Source | 700,000Source | 600,000Source | 900,000Source | 500,000Source | 900,000Source | 2,800,000Source | 2,500,000Source | 1,700,000Source | 1,500,000Source |
| Other Nonoperating Income (Expense)USD | — | — | — | — | — | — | — | — | 2,251,000Source | — | — | — |
| Payments of Financing CostsUSD | — | — | — | — | — | — | 0Source | 534,000Source | 11,899,000Source | 17,163,000Source | — | — |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 908,000Source | 1,082,000Source | 10,111,000Source | 4,458,000Source | 375,000Source | 939,000Source |
| Restructuring CostsUSD | — | — | — | — | — | — | — | — | — | — | — | 7,000Source |
| Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | — | — | — | — | — | — | — | — | — | — | — | — |
| Gain (Loss) on Extinguishment of Debt | — | — | — | — | —Source | —Source | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 13,120,000Source | 727,000Source | 31,687,000Source | 4,833,000Source | 83,228,000Source | 3,084,000Source | 62,902,000Source | 7,873,000Source | — | — |
| Cost of RevenueUSD | — | — | 3,349,000Source | 1,515,000Source | — | 2,576,000Source | — | 2,094,000Source | — | 7,078,000Source | — | — |
| Selling, General and Administrative ExpenseUSD | — | — | 37,359,000Source | 19,582,000Source | 42,591,000Source | 38,484,000Source | 38,309,000Source | 35,393,000Source | 151,562,000Source | 69,233,000Source | — | — |
| Operating Income (Loss)USD | — | — | -56,434,000Source | -48,101,000Source | -51,036,000Source | -63,589,000Source | 3,881,000Source | -59,004,000Source | -213,064,000Source | -592,627,000Source | -99,822,000Source | -119,734,000Source |
| Other Nonoperating Income (Expense)USD | — | — | — | — | — | — | — | — | 2,251,000Source | — | — | — |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -55,792,000Source | -41,210,000Source | -62,840,000Source | -59,007,000Source | 5,397,000Source | -53,236,000Source | -204,627,000Source | -567,939,000Source | -75,802,000Source | -104,199,000Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -55,792,000Source | -41,210,000Source | -62,840,000Source | -59,007,000Source | 5,397,000Source | -53,236,000Source | -204,627,000Source | -567,939,000Source | -75,802,000Source | -104,199,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.16Source | -0.15Source | -0.18Source | -0.17Source | 0.02Source | -0.16Source | -0.6Source | -2.11Source | -0.35Source | -0.48Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.16Source | -0.15Source | -0.18Source | -0.17Source | 0.01Source | -0.16Source | -0.6Source | -2.11Source | -0.35Source | -0.48Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 342,393Source | 273,565Source | 348,770Source | 340,746Source | 347,332Source | 338,612Source | 341,541Source | 268,772Source | 218,880Source | 216,721Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 342,393Source | 273,565Source | 348,770Source | 340,746Source | 377,521Source | 338,612Source | 341,541Source | 268,772Source | 218,880Source | 216,721Source |
| Interest Expense (non-operating)USD | — | — | 6,534,000Source | 120,000Source | 6,759,000Source | 421,000Source | 6,708,000Source | 54,000Source | 13,682,000Source | 341,000Source | — | — |
| Additional Financial Items | ||||||||||||
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | — | — | — | — | 536,000Source | 310,000Source | 1,739,000Source | 683,000Source | 222,000Source | 199,000Source |
| General and Administrative ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 28,533,000Source | 31,919,000Source |
| Gross ProfitUSD | — | — | 9,771,000Source | -788,000Source | — | 2,257,000Source | — | 990,000Source | — | 795,000Source | — | — |
| Interest Income, OtherUSD | — | — | 6,033,000Source | 6,726,000Source | 4,596,000Source | 4,780,000Source | 5,108,000Source | 5,321,000Source | 21,430,000Source | 27,062,000Source | 24,611,000Source | 7,448,000Source |
| Market Risk Benefit, Change in Fair Value, Gain (Loss)USD | — | — | — | 500,000Source | — | — | — | -800,000Source | 800,000Source | 900,000Source | 500,000Source | 10,200,000Source |
| Nonoperating Income (Expense)USD | — | — | 642,000Source | 6,891,000Source | -11,804,000Source | 4,582,000Source | 1,516,000Source | 5,768,000Source | 8,437,000Source | 24,688,000Source | 24,020,000Source | 15,535,000Source |
| Operating ExpensesUSD | — | — | 66,205,000Source | 47,313,000Source | 82,723,000Source | 68,422,000Source | 79,347,000Source | 62,088,000Source | 275,966,000Source | 593,422,000Source | 99,822,000Source | 119,734,000Source |
| Operating Lease, ExpenseUSD | — | — | 500,000Source | 700,000Source | 600,000Source | 900,000Source | 500,000Source | 900,000Source | 2,800,000Source | 2,500,000Source | 1,700,000Source | 1,500,000Source |
| Research and Development ExpenseUSD | — | — | 28,846,000Source | 27,731,000Source | 30,661,000Source | 27,362,000Source | 35,047,000Source | 24,601,000Source | 115,106,000Source | 99,119,000Source | 71,289,000Source | 87,815,000Source |
| Restructuring CostsUSD | — | — | — | — | — | — | — | — | — | — | — | 7,000Source |
| Selling ExpenseUSD | — | — | — | — | 911,000Source | 172,000Source | 375,000Source | 0Source | 856,000Source | — | — | — |
| Interest Expense | — | — | —Source | — | — | —Source | — | — | — | — | — | — |
| Other Income | — | — | —Source | —Source | —Source | —Source | —Source | —Source | — | — | — | — |
Filing attachments
d261840dex991.htm · 8-K · 2026-08-06
EX-99.1 2 d261840dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Nuvation Bio Reports Second Quarter 2026 Financial Results and Provides Business Update Achieved $31.7 million in second quarter 2026 total revenue, including $23.2 million in net product revenue for IBTROZI® (taletrectinib) IBTROZI is the most prescribed ROS1 TKI in in both first-line and overall new patient starts in 2026 based on IQVIA claims from first five months of the year ~85% of the approximately 160 new patients were TKI…
Read attachment ↗d136399dex991.htm · 8-K · 2026-07-06
EX-99.1 2 d136399dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Nuvation Bio Inc. Announces Full Exercise of Greenshoe Option in $287.5 Million Convertible Senior Notes Offering NEW YORK, July 6, 2026 - Nuvation Bio Inc. (“Nuvation Bio”) (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that the underwriters have exercised in full their over-allotment option (the “Greenshoe Exercise”) to purchase an additional $37.5 …
Read attachment ↗d81296dex41.htm · 8-K · 2026-06-30
EX-4.1 3 d81296dex41.htm EX-4.1 EX-4.1 Exhibit 4.1 NUVATION BIO INC., Issuer AND U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, Trustee INDENTURE Dated as of June 30, 2026 Debt Securities T ABLE O F C ONTENTS PAGE ARTICLE 1 DEFINITIONS …
Read attachment ↗d81296dex42.htm · 8-K · 2026-06-30
EX-4.2 4 d81296dex42.htm EX-4.2 EX-4.2 Exhibit 4.2 NUVATION BIO INC. AND U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as Trustee FIRST SUPPLEMENTAL INDENTURE Dated as of June 30, 2026 0.75% Convertible Senior Notes due 2032 TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS; RULES OF CONSTRUCTION; SCOPE AND INTERPRETATION OF BASE INDENTURE Section 1.01. Definitions …
Read attachment ↗d81296dex991.htm · 8-K · 2026-06-30
EX-99.1 8 d81296dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Nuvation Bio Announces Proposed Convertible Senior Notes Offering NEW YORK, June 25, 2026 - Nuvation Bio Inc. (“Nuvation Bio”) (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced its intent to offer, subject to market conditions and other factors, $200.0 million aggregate principal amount of Convertible Senior Notes due in 2032 (the “Notes”) in an underwritt…
Read attachment ↗d81296dex992.htm · 8-K · 2026-06-30
EX-99.2 9 d81296dex992.htm EX-99.2 EX-99.2 Exhibit 99.2 Nuvation Bio Announces Pricing of Upsized Offering of $250.0 million of Convertible Senior Notes NEW YORK, June 25, 2026 - Nuvation Bio Inc. (“Nuvation Bio”) (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced the pricing of its underwritten offering (the “Offering”) of $250.0 million aggregate principal amount of 0.75% Convertible Senior Notes due in 2032 …
Read attachment ↗